#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA3821983	B	Competitive inhibition of wild type beta-catenin (unknown origin) expressed in Escherichia coli BL21 DE3 interaction with N-terminally biotinylated human BCL9 (350 to 375 residues) by alpha screen assay	Homo sapiens	23		assay format	Scientific Literature
2.	ALA4419373	B	Inhibition of C-terminal 6x-histidine tagged beta-catenin (138 to 686 residues) (unknown origin) expressed in Escherichia coli BL21 DE3 /human BCL9 (350 to 375 residues) protein-protein interactions incubated for 1 hr by Alpha-screen assay	Homo sapiens	57		assay format	Patent Bioactivity Data
3.	ALA4419380	B	Inhibition of inhibited beta-catenin D145A mutant (unknown origin) expressed in Escherichia coli BL21 DE3 /human BCL9 (350 to 375 residues) protein-protein interactions by Alpha-screen assay	Homo sapiens	3		assay format	Patent Bioactivity Data
4.	ALA4419381	B	Inhibition of inhibited beta-catenin E155A mutant (unknown origin) expressed in Escherichia coli BL21 DE3 /human BCL9 (350 to 375 residues) protein-protein interactions by Alpha-screen assay	Homo sapiens	3		assay format	Patent Bioactivity Data
5.	ALA4419382	B	Inhibition of inhibited beta-catenin D145A/E155A mutant (unknown origin) expressed in Escherichia coli BL21 DE3 /human BCL9 (350 to 375 residues) protein-protein interactions by Alpha-screen assay	Homo sapiens	3		assay format	Patent Bioactivity Data
6.	ALA4419401	B	Inhibition of beta-catenin/BCL9 (unknown origin) expressed in Wnt-activated HEK293 cells assessed as reduction in canonical Wnt signaling transactivation by Wnt-responsive luciferase reporter assay	Homo sapiens	2		cell-based format	Patent Bioactivity Data
7.	ALA4419402	B	Inhibition of beta-catenin/BCL9 in Wnt-activated human SW480 cells assessed as reduction in canonical Wnt signaling transactivation by Wnt-responsive luciferase reporter assay	Homo sapiens	3		cell-based format	Patent Bioactivity Data
8.	ALA4419403	B	Inhibition of beta-catenin/BCL9 in Wnt-activated human MDA-MB-231 cells assessed as reduction in canonical Wnt signaling transactivation by Wnt-responsive luciferase reporter assay	Homo sapiens	2		cell-based format	Patent Bioactivity Data
9.	ALA4419404	B	Inhibition of beta-catenin/BCL9 in human MDA-MB-231 cells assessed as Axin2 mRNA expression at 1 uM by quantitative real-time PCR analysis based cell based assay relative to control	Homo sapiens	1		cell-based format	Patent Bioactivity Data
10.	ALA4419405	B	Inhibition of beta-catenin/BCL9 in human MDA-MB-231 cells assessed as Axin2 mRNA expression at 2 uM by quantitative real-time PCR analysis based cell based assay relative to control	Homo sapiens	1		cell-based format	Patent Bioactivity Data
11.	ALA4419406	B	Inhibition of beta-catenin/BCL9 in human MDA-MB-231 cells assessed as Axin2 mRNA expression at 4 uM by quantitative real-time PCR analysis based cell based assay relative to control	Homo sapiens	1		cell-based format	Patent Bioactivity Data
12.	ALA4419407	B	Inhibition of beta-catenin/BCL9 in human MDA-MB-231 cells assessed as LGR5 mRNA expression at 1 uM by quantitative real-time PCR analysis based cell based assay relative to control	Homo sapiens	1		cell-based format	Patent Bioactivity Data
13.	ALA4419408	B	Inhibition of beta-catenin/BCL9 in human MDA-MB-231 cells assessed as LGR5 mRNA expression at 2 uM by quantitative real-time PCR analysis based cell based assay relative to control	Homo sapiens	1		cell-based format	Patent Bioactivity Data
14.	ALA4419409	B	Inhibition of beta-catenin/BCL9 in human MDA-MB-231 cells assessed as LGR5 mRNA expression at 4 uM by quantitative real-time PCR analysis based cell based assay relative to control	Homo sapiens	1		cell-based format	Patent Bioactivity Data
15.	ALA4419410	B	Inhibition of beta-catenin/BCL9 in human MDA-MB-231 cells assessed as LEF1 mRNA expression at 1 uM by quantitative real-time PCR analysis based cell based assay relative to control	Homo sapiens	1		cell-based format	Patent Bioactivity Data
16.	ALA4419411	B	Inhibition of beta-catenin/BCL9 in human MDA-MB-231 cells assessed as LEF1 mRNA expression at 2 uM by quantitative real-time PCR analysis based cell based assay relative to control	Homo sapiens	1		cell-based format	Patent Bioactivity Data
17.	ALA4419412	B	Inhibition of beta-catenin/BCL9 in human MDA-MB-231 cells assessed as LEF1 mRNA expression at 4 uM by quantitative real-time PCR analysis based cell based assay relative to control	Homo sapiens	1		cell-based format	Patent Bioactivity Data
18.	ALA4419413	B	Inhibition of beta-catenin/BCL9 in human MDA-MB-231 cells assessed as cyclin D1 mRNA expression at 1 uM by quantitative real-time PCR analysis based cell based assay relative to control	Homo sapiens	1		cell-based format	Patent Bioactivity Data
19.	ALA4419414	B	Inhibition of beta-catenin/BCL9 in human MDA-MB-231 cells assessed as cyclin D1 mRNA expression at 2 uM by quantitative real-time PCR analysis based cell based assay relative to control	Homo sapiens	1		cell-based format	Patent Bioactivity Data
20.	ALA4419415	B	Inhibition of beta-catenin/BCL9 in human MDA-MB-231 cells assessed as cyclin D1 mRNA expression at 4 uM by quantitative real-time PCR analysis based cell based assay relative to control	Homo sapiens	1		cell-based format	Patent Bioactivity Data